Skip to main content

Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · Delayed Price · USD
13.68
-0.11 (-0.78%)
After-hours:Oct 22, 2021 4:01 PM EDT
13.79
-0.10 (-0.72%)
At close: Oct 22, 4:00 PM
Market Cap3.33B
Revenue (ttm)8.46M
Net Income (ttm)n/a
Shares Out42.71M
EPS (ttm)-8.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume112,801
Open13.83
Previous Close13.89
Day's Range13.46 - 13.83
52-Week Range10.62 - 19.84
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateOct 28, 2021

About LYEL

Lyell Immunopharma is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We believe the key to effective cell therapy is the mastery of the identity, fate and function of cells to create living medicines. We take a systematic, interrogative, cell biology-driven approach to overcome what we view as the two major barriers to successful ACT – (1) T cell exhaustion and (2) lack of durable stemness – through the application of our proprietary genetic and epigenetic reprogramming technologies, G...

IndustryBiotechnology
IPO DateJun 17, 2021
CEOElizabeth Homans
Employees188
Stock ExchangeNASDAQ
Ticker SymbolLYEL
Full Company Profile

Financial Performance

In 2020, LYEL's revenue was $7.76 million, an increase of 1,080.52% compared to the previous year's $657,000. Losses were -$204.47 million, 58.0% more than in 2019.

Financial Statements

News

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with...

1 month ago - GlobeNewsWire

Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...

2 months ago - GlobeNewsWire

Lyell Immunopharma Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...

4 months ago - GlobeNewsWire

Lyell Immunopharma IPO Registration Document (S-1)

Lyell Immunopharma, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC